Table 2

Adverse drug reactions in patients not exposed to cancer chemotherapy

ATC*DrugAgeAdverse drug eventNaranjo scoreAvoidable?Licensing state
JDKTP/HIB vaccineBaby/toddlerDyspnoea5NoLicensed
JDKTP/HIB vaccineBaby/toddlerFever, vomiting6NoLicensed
JDKTP/HIB vaccineBaby/toddlerFever6NoLicensed
JDKTP/HIB vaccineBaby/toddlerFever, refusal of foodNo
Pneumococcal vaccine4Licensed
JDKTP/HIB vaccineBaby/toddlerFeverNo
Pneumococcal vaccine4Licensed
LInfliximabChildFever, tachycardia, abdominal pain6NoLicensed
LThymocytenglobulineChildSerum sickness6NoUnlicensed
NLithium (transmission through placenta)NewbornSyncope6NoUnlicensed
NValproic acidChildDrowsiness8YesLicensed
  • *Anatomical Therapeutical Chemical (ATC) classification system of the WHO. A, alimentary tract and metabolism; C, cardiovascular system; J, anti-infectives for systemic use; L, antineoplastic and immunomodulating agents N, nervous system.15

  • Patient age by means of EMeA criteria: preterm, newborn (0–1 month), baby/toddler (1 month–2 years), child (2–11 years) and adolescent (12–18 years).

  • Probability measured by Naranjo score: ≤0 Adverse Drug Reactions (ADR) doubtful, 1–4 ADR possible, 5–8 ADR likely, ≥9 ADR certain.11

  • DKTP, Difteria Pertussis Tetanus Polio vaccin; EMeA, European Medicines (Evaluation) Agency; HIB, Haemophylus Influenza B vaccin.